The exact incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) remains unknown. It is estimated that NAFLD affects 20% to 40% of the Western world, with the Asian and Pacific regions being less affected.[3] The majority of cases occur in people between the ages of 40-60 years, but NAFLD is becoming increasingly prevalent in the paediatric population.[4] Although initially thought to be a disease primarily affecting women, NAFLD is now known to affect the sexes equally. Ethnic differences seem to play a role in the prevalence of fatty liver in the US, with Hispanic people more affected than white people. There is some evidence to suggest that African-Americans are less susceptible to the progressive form of the disease.

BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.

To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.

You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.

Use of this content is subject to our disclaimer